New AvidXchange Report Shows Finance Teams More Prepared Than in 2020—But Still Investing to Weather Uncertainty Oncternal Therapeutics Announces Appointment of Salim Yazji as Chief Medical Officer
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
Acer Therapeutics Reports Q1 2021 Financial Results and Provides Corporate Update
NEWTON, Mass., May 17, 2021 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
NexImmune Reports First Quarter 2021 Financial Results and Recent Updates
Advancing two lead product candidates in Phase 1/2 clinical trials Completed successful $126M initial public…
Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase III study protocol for its treatment of distal renal tubular acidosis (dRTA)
Advicenne receives positive feedback from the US FDA on pathway to approval and amended Phase…
Advicenne reçoit un avis positif de la FDA sur la procédure d’approbation et l’Agence accepte le protocole modifié de l’étude de phase III pour son traitement de l’acidose tubulaire rénale distale (ATRd)
Advicenne reçoit un avis positif de la FDA sur la procédure d’approbation et l’Agence accepte…
NTG Nordic Transport Group publishes interim report for Q1 2021
Company announcement no. 16 – 2117 May 2021 NTG Nordic Transport Group publishes interim report…
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of…
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 17 May 2021 – On 7…
Report from LIDDS Annual General Meeting 2021
UPPSALA, SWEDEN – LIDDS Annual General Meeting (AGM) was held on May 17, 2021….
Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children
Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks…
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:…
Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a…
Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRx’s Proprietary Klarity-C® Drops
Multi-center Retrospective Study Demonstrates Statistically Significant Reduction in Signs and Symptoms of Dry Eye Disease…
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS17 MAY 2021 at 16.00 EEST …
Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study
THCVHS combined with netarsudil (Rhopressa®) achieves an average maximum intraocular pressure (IOP) reduction of…
SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update
Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from…
Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy™
Clinically meaningful and statistically significant reduction of 16.6 mmHg in systolic blood pressure out to…
Bioventus Senior Management to Present at Upcoming Investor Conferences
DURHAM, N.C., May 17, 2021 (GLOBE NEWSWIRE) — Senior management of Bioventus Inc. (Nasdaq: BVS)…
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic…
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader…